Physician profile
Ann Chartrand
NPI 1336678366
$6,627.36
in general payments reported to CMS, 2019-2025
33 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,885 · 2022: $986 · 2023: $1,361 · 2024: $1,180 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,711 · Education: $45.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.96 |
| Education | $45.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,151.33 | 2021-2025 | |
| Validus Pharmaceuticals LLC | $688.68 | 2021-2023 | Equetro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $489.57 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $475.70 | 2021-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $365.65 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $332.21 | 2021-2025 | Trintellix |
| Corium, LLC | $305.51 | 2022-2024 | Azstarys |
| Bausch Health US, LLC | $291.80 | 2021-2024 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $284.33 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $229.71 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $198.72 | 2021-2022 | |
| Alkermes, INC. | $193.26 | 2021-2024 | Aristada, Lybalvi |
| Harmony Biosciences LLC | $177.67 | 2024 | |
| Vanda Pharmaceuticals INC. | $173.19 | 2021-2024 | Fanapt |
| Neurocrine Biosciences, INC. | $161.14 | 2021-2024 | Ingrezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $125.67 | 2021-2024 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $117.26 | 2021-2024 | Qelbree, Qelbree |
| Avanir Pharmaceuticals, INC. | $115.07 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $110.87 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $86.50 | 2021 | |
| Tris Pharma INC | $82.68 | 2023-2024 | Dyanavel Xr |
| Novo Nordisk INC | $69.80 | 2021-2023 | Wegovy |
| Acadia Pharmaceuticals INC | $69.40 | 2022-2023 | Nuplazid |
| Neos Therapeutics, LP | $66.50 | 2022 | |
| Ironshore Pharmaceuticals INC. | $58.38 | 2022-2024 | |
| Adlon Therapeutics L.P. | $36.85 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $36.40 | 2024 | |
| Sage Therapeutics, LLC | $35.33 | 2024 | |
| Eisai INC. | $31.92 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.84 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $16.50 | 2022 | |
| Owp Pharmaceuticals, INC. | $16.40 | 2021 | |
| Livanova USA, INC. | $15.52 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Chartrand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.